Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49712 | 35661987 | Hormones (Athens) | Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. | 2022 | Details |
| A49714 | 35661191 | Aliment Pharmacol Ther | Review article: vascular effects of PPARs in the context of NASH. | 2022 | Details |
| A49718 | 35659603 | Clin Res Hepatol Gastroenterol | Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A49723 | 35657576 | Clin Rev Allergy Immunol | Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature. | 2022 | Details |
| A49724 | 35657189 | Rev Med Liege | [Non-alcoholic steatohepatitis (NASH) : a model of metabolic inflammation («metaflammation»)]. | 2022 | Details |
| A49725 | 35657127 | Arch Endocrinol Metab | Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes. | 2022 | Details |
| A49726 | 35657121 | J Viral Hepat | Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents. | 2022 | Details |
| A49731 | 35655171 | BMC Gastroenterol | Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma. | 2022 | Details |
| A49736 | 35654350 | J Ethnopharmacol | Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK. | 2022 | Details |
| A49737 | 35654298 | Clin Gastroenterol Hepatol | Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients. | 2022 | Details |
| A49744 | 35651885 | Metabol Open | Effect of 8 Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery. | 2022 | Details |
| A49752 | 35647690 | Microbiol Spectr | Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. | 2022 | Details |
| A49753 | 35647047 | Front Cardiovasc Med | Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. | 2022 | Details |
| A49755 | 35646285 | World J Gastrointest Oncol | Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. | 2022 | Details |
| A49757 | 35646268 | World J Hepatol | Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis. | 2022 | Details |
| A49760 | 35645140 | Saudi J Gastroenterol | Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study. | 2022 | Details |
| A49764 | 35643936 | Liver Int | Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. | 2022 | Details |
| A49767 | 35643859 | Lab Invest | A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. | 2022 | Details |
| A49770 | 35643287 | J Nutr Biochem | Opisthorchis viverrini infection induces metabolic disturbances in hamsters fed with high fat/high fructose diets: Implications for liver and kidney pathologies. | 2022 | Details |
| A49776 | 35641932 | BMC Endocr Disord | Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. | 2022 | Details |
| A49780 | 35639554 | J Gastroenterol Hepatol | GGT dynamic for advanced fibrosis in NAFLD: Novel but not convincing. | 2022 | Details |
| A49784 | 35639028 | FASEB J | A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. | 2022 | Details |
| A49793 | 35636146 | Neoplasia | Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis. | 2022 | Details |
| A49794 | 35635899 | Nutr Res | Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis. | 2022 | Details |
| A49795 | 35635761 | Liver Int | Comparison of point-shear wave elastography (ElastPQ) and transient elastography (FibroScan) for liver fibrosis staging in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A49797 | 35635048 | Ann Med | Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. | 2022 | Details |
| A49799 | 35634402 | Front Nutr | Liver Protein Expression in NASH Mice on a High-Fat Diet: Response to Multi-Mineral Intervention. | 2022 | Details |
| A49800 | 35634340 | Front Immunol | The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment. | 2022 | Details |
| A49808 | 35630668 | Molecules | Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers. | 2022 | Details |
| A49810 | 35630058 | Medicina (Kaunas) | Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. | 2022 | Details |
| A49818 | 35628889 | J Clin Med | Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. | 2022 | Details |
| A49822 | 35628360 | Int J Mol Sci | Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A49825 | 35626354 | Diagnostics (Basel) | Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. | 2022 | Details |
| A49827 | 35625927 | Biomedicines | A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. | 2022 | Details |
| A49831 | 35625660 | Biomolecules | Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and In Vitro Studies. | 2022 | Details |
| A49832 | 35625625 | Biomolecules | Extracellular Vesicles from Steatotic Hepatocytes Provoke Pro-Fibrotic Responses in Cultured Stellate Cells. | 2022 | Details |
| A49835 | 35625413 | Biology (Basel) | Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth. | 2022 | Details |
| A49837 | 35624786 | Antioxidants (Basel) | The Role and Mechanisms of Selenium Supplementation on Fatty Liver-Associated Disorder. | 2022 | Details |
| A49841 | 35624731 | Antioxidants (Basel) | Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A49847 | 35622622 | Toxics | Bisphenol A Coupled with a High-Fat Diet Promotes Hepatosteatosis through Reactive-Oxygen-Species-Induced CD36 Overexpression. | 2022 | Details |
| A49852 | 35618435 | Neurology | Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study. | 2022 | Details |
| A49857 | 35617294 | PLoS One | Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. | 2022 | Details |
| A49859 | 35616321 | Clin Transl Gastroenterol | Association of serum and fecal bile acid patterns with liver fibrosis in biopsy-proven nonalcoholic fatty liver disease: An observational study. | 2022 | Details |
| A49863 | 35615095 | Front Med (Lausanne) | Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease - A Systematic Review and Meta-Analysis. | 2022 | Details |
| A49864 | 35614939 | Front Pharmacol | Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A49871 | 35613944 | J Gastroenterol Hepatol | Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation. | 2022 | Details |
| A49878 | 35611380 | Pediatr Gastroenterol Hepatol Nutr | Correlation between Transient Elastography (Fibroscan®) and Ultrasonographic and Computed Tomographic Grading in Pediatric Nonalcoholic Steatohepatitis. | 2022 | Details |
| A49879 | 35611223 | JMA J | Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History. | 2022 | Details |
| A49881 | 35610402 | Pharm Res | Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application. | 2022 | Details |
| A49882 | 35609858 | J Nutr Biochem | Phloretin mitigates oxidative injury, inflammation, and fibrogenic responses via restoration of autophagic flux in in vitro and preclinical models of NAFLD. | 2022 | Details |
| A49883 | 35609854 | J Nutr Biochem | Excess fructose enhances oleatic cytotoxicity via reactive oxygen species production and causes necroptosis in hepatocytes. | 2022 | Details |
| A49884 | 35609372 | Biomed Pharmacother | Roles of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in non-neoplastic liver diseases. | 2022 | Details |
| A49886 | 35608296 | Clin Transl Gastroenterol | The ability of lipoprotein (a) level to predict early carotid atherosclerosis is impaired in patients with advanced liver fibrosis related to metabolic associated fatty liver disease. | 2022 | Details |
| A49890 | 35605893 | Clin Res Hepatol Gastroenterol | The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound. | 2022 | Details |
| A49900 | 35603860 | Nutr Health | Decreased Serum zinc, selenium, and vitamin E as possible risk factors of hepatic fibrosis in non-alcoholic fatty liver disease. | 2022 | Details |
| A49901 | 35603482 | Hepatology | PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference. | 2022 | Details |
| A49903 | 35603224 | Front Immunol | Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A49904 | 35603209 | Front Immunol | Liver Stiffness by Transient Elastography Correlates With Degree of Portal Hypertension in Common Variable Immunodeficiency Patients With Nodular Regenerative Hyperplasia. | 2022 | Details |
| A49905 | 35602098 | Oxid Med Cell Longev | A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. | 2022 | Details |
| A49907 | 35600209 | Can J Gastroenterol Hepatol | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. | 2022 | Details |
| A49908 | 35599934 | Ann Gastroenterol | Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease. | 2022 | Details |
| A49910 | 35599922 | Ann Gastroenterol | Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. | 2022 | Details |
| A49911 | 35599680 | Paediatr Child Health | Awareness, management, and practice patterns of pediatric NAFLD by primary care physicians. | 2021 | Details |
| A49914 | 35598367 | Biomed Pharmacother | Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. | 2022 | Details |
| A49915 | 35598211 | Orv Hetil | A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. | 2022 | Details |
| A49927 | 35592121 | Front Surg | Changes in Indices of Steatosis and Fibrosis in Liver Grafts of Living Donors After Weight Reduction. | 2022 | Details |
| A49934 | 35589256 | J Hepatol | Impact of non-invasive biomarkers on hepatology practice: Past, present and future. | 2022 | Details |
| A49935 | 35589249 | J Hepatol | Breakthroughs in therapies for NASH and remaining challenges. | 2022 | Details |
| A49938 | 35588334 | Cell Mol Life Sci | Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway. | 2022 | Details |
| A49939 | 35588190 | Hepatology | Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. | 2022 | Details |
| A49940 | 35587726 | J Gastroenterol Hepatol | Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease. | 2022 | Details |
| A49942 | 35586979 | Hepatology | Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. | 2022 | Details |
| A49943 | 35586202 | Diabetes Metab Syndr Obes | The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. | 2022 | Details |
| A49944 | 35586049 | Front Pharmacol | Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice. | 2022 | Details |
| A49948 | 35585153 | Sci Rep | Incremental levels of diagnostic information incentivize health-seeking in non-alcoholic fatty liver: a randomized clinical trial. | 2022 | Details |
| A49949 | 35584952 | Magn Reson Med Sci | Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49950 | 35584814 | Annu Rev Nutr | Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis. | 2022 | Details |
| A49955 | 35583480 | J Agric Food Chem | Spermidine Ameliorates Nonalcoholic Steatohepatitis through Thyroid Hormone-Responsive Protein Signaling and the Gut Microbiota-Mediated Metabolism of Bile Acids. | 2022 | Details |
| A49956 | 35583419 | Minerva Med | Non-invasive biochemical markers and surrogate scores in evaluating non-alcoholic steatohepatitis. A narrative review. | 2022 | Details |
| A49961 | 35582126 | World J Gastroenterol | Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49962 | 35581956 | Hepatol Commun | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | 2022 | Details |
| A49967 | 35579278 | Mol Syst Biol | Dynamic human liver proteome atlas reveals functional insights into disease pathways. | 2022 | Details |
| A49968 | 35578969 | Compr Physiol | Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases. | 2022 | Details |
| A49971 | 35578028 | Inflamm Res | Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet. | 2022 | Details |
| A49973 | 35577161 | J Ethnopharmacol | Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo. | 2022 | Details |
| A49976 | 35576742 | Phytomedicine | Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy. | 2022 | Details |
| A49978 | 35574998 | Liver Int | Attribution of diabetes to the development of severe liver disease in the general population. | 2022 | Details |
| A49982 | 35573018 | Front Med (Lausanne) | Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. | 2022 | Details |
| A49990 | 35569823 | Korean J Intern Med | Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. | 2022 | Details |
| A49995 | 35568114 | J Ethnopharmacol | Ethanol extract of Pharbitis nil ameliorates liver fibrosis through regulation of the TGFβ1-SMAD2/3 pathway. | 2022 | Details |
| A49996 | 35568098 | J Nutr Biochem | Indole supplementation ameliorates MCD-induced NASH in mice. | 2022 | Details |
| A49998 | 35567505 | FASEB J | Mesencephalic astrocyte-derived neurotrophic factor alleviates non-alcoholic steatohepatitis induced by Western diet in mice. | 2022 | Details |
| A50000 | 35566749 | J Clin Med | Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease. | 2022 | Details |
| A50001 | 35566592 | J Clin Med | Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. | 2022 | Details |
| A50002 | 35566571 | J Clin Med | Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. | 2022 | Details |
| A50013 | 35563534 | Int J Mol Sci | Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A50014 | 35563425 | Int J Mol Sci | Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis. | 2022 | Details |
| A50016 | 35563210 | Int J Mol Sci | Liver Steatosis: A Marker of Metabolic Risk in Children. | 2022 | Details |
| A50019 | 35562689 | BMC Endocr Disord | Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years. | 2022 | Details |